Evidence map›Paper›PMID 40421268›Full record

ArticleFrontiers in chemistry2025

Identification of novel potential hypoxia-inducible factor-1α inhibitors through machine learning and computational simulations.

Yuxiang He, Shuning Diao, Shengzhen Hou, Taiying Li, Wenhui Meng, Jinping Zhang

Abstract read
In one paragraph

Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yuxiang HeFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Shuning DiaoFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Shengzhen HouFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Taiying LiFirst Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.
Wenhui MengThird Department of Infectious Diseases, The Fourth People's Hospital of Zibo, Zibo, China.
Jinping ZhangAffiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Hypoxia-inducible factor-1α (HIF-1α) has become a significant therapeutic target for breast cancer and other cancers by regulating the expression of downstream genes such as erythropoietin, thereby improving cell survival in hypoxic conditions. Methods: We jointly applied a multistage screening system encompassing machine learning, molecular docking, and molecular dynamics simulations to conduct virtual screening of the "Traditional Chinese Medicine Monomer Library" for potential HIF-1α inhibitors. The virtual screening was conducted in three sequential stages, applying the following selection criteria sequentially: an activity prediction score greater than or equal to 0.8, a stronger binding affinity, and an MM-PBSA binding free energy lower than the reference compound. Results and Discussion: We retrieved 361 compounds with HIF-1α inhibitory activity data from the ChEMBL database for the construction and evaluation of machine learning models. Among the six constructed models, the random forest model based on RDKit molecular descriptor with the optimal comprehensive performance was employed for virtual screening. Ultimately, four compounds were selected for binding mode analyses and 100 ns molecular dynamics simulations. The results showed that the compounds Arnidiol and Epifriedelanol exhibit the most stable interactions with the HIF-1α protein, which can serve as potential HIF-1α inhibitors for future investigations.

Indexed as

hypoxia-inducible factor-1αmachine learningmolecular dockingmolecular dynamics simulationvirtual screening

Identifiers

PMID40421268
PMCPMC12104167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.